SAMSUNG BIOLOGICS CO.,LTD.

207940.KSSouth Korea

39 filed reports · 509 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

₩4.56T

FY2025 · to Dec 31, 2025

up +30.3% vs ₩3.5T

Annual report

Net income

₩1.78T

FY2025 · to Dec 31, 2025

up +64.7% vs ₩1.08T

Annual report

Operating income

₩2.07T

FY2025 · to Dec 31, 2025

up +56.6% vs ₩1.32T

Annual report

Latest quarter

Revenue

₩1.49T

Q3 FY2026 · to Sep 30, 2026

down −10.2% vs ₩1.66T

Q3 report

Net income

₩391B

Q3 FY2026 · to Sep 30, 2026

down −31.9% vs ₩574B

Q3 report

Operating income

₩640B

Q3 FY2026 · to Sep 30, 2026

down −12.2% vs ₩729B

Q3 report

Filed reports

39 reports · Mar 2017 to Sep 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Half Year · 11012DART104,169Jun 2017 to Jun 2026
Q1 · 11013DART103,661Mar 2017 to Mar 2026
Q3 · 11014DART104,216Sep 2017 to Sep 2026
Annual · 11011DART93,112Dec 2017 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q3110142026-09-302026-11-16856Open
FY2026 H1110122026-06-302026-08-14922Open
FY2026 Q1110132026-03-312026-05-15758Open
FY2025110112025-12-312026-05-15886Open
FY2025 Q3110142025-09-302025-11-14761Open
FY2025 H1110122025-06-302025-08-14717Open
FY2025 Q1110132025-03-312025-05-15642Open
FY2024110112024-12-312025-08-14586Open
FY2024 Q3110142024-09-302024-11-14730Open
FY2024 H1110122024-06-302024-08-14705Open
FY2024 Q1110132024-03-312024-05-16624Open
FY2023110112023-12-312024-03-07764Open

Financial data

509 concepts · 15,158 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

IFRS494 concepts · 14,222 facts · Dec 2014 to Sep 2026

  • Stockholders Equity126 · Dec 2015 to Sep 2026
  • Accounts Payable120 · Dec 2015 to Sep 2026
  • Capital surplus120 · Dec 2015 to Sep 2026
  • Cash and Equivalents120 · Dec 2015 to Sep 2026
  • Inventory120 · Dec 2015 to Sep 2026
  • Long-term trade and other non-current payables120 · Dec 2015 to Sep 2026
  • Other Comprehensive income/loss accumulated amount120 · Dec 2015 to Sep 2026
  • Property, Plant & Equipment, Net120 · Dec 2015 to Sep 2026
  • Retained Earnings (Accumulated Deficit)120 · Dec 2015 to Sep 2026
  • Total Assets120 · Dec 2015 to Sep 2026
  • Total Current Assets120 · Dec 2015 to Sep 2026
  • Total Current Liabilities120 · Dec 2015 to Sep 2026
  • Total Equity and Liabilities120 · Dec 2015 to Sep 2026
  • Total Liabilities120 · Dec 2015 to Sep 2026
  • Total Noncurrent Assets120 · Dec 2015 to Sep 2026
  • Total Noncurrent Liabilities120 · Dec 2015 to Sep 2026
  • Trade and Other Current Receivables120 · Dec 2015 to Sep 2026
  • Other Noncurrent Financial Assets118 · Dec 2015 to Sep 2026
  • Issued Share Capital115 · Dec 2016 to Sep 2026
  • Long-term deposits not classified as cash equivalents115 · Dec 2016 to Sep 2026
  • Other Current Financial Assets115 · Dec 2016 to Sep 2026
  • Cost of Revenue114 · Dec 2015 to Sep 2026
  • Finance Income114 · Dec 2015 to Sep 2026
  • Gross Profit114 · Dec 2015 to Sep 2026

Segment15 concepts · 936 facts · Dec 2022 to Sep 2026

  • Revenue368 · Dec 2022 to Sep 2026
  • Cost of Revenue98 · Dec 2022 to Sep 2026
  • Depreciation, property, plant and equipment62 · Dec 2022 to Sep 2026
  • Operating Income62 · Dec 2022 to Sep 2026
  • Amortisation, intangible assets other than goodwill50 · Dec 2023 to Sep 2026
  • Additions to non-current assets other than financial instruments, deferred tax assets, net defined benefit assets, and rights arising under insurance contracts43 · Dec 2023 to Sep 2026
  • Investments Accounted for Using the Equity Method37 · Dec 2023 to Sep 2026
  • Total Assets37 · Dec 2023 to Sep 2026
  • Total Liabilities37 · Dec 2023 to Sep 2026
  • Internal revenue36 · Dec 2022 to Sep 2025
  • Revenue, Gross36 · Dec 2022 to Sep 2025
  • Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts30 · Dec 2023 to Sep 2026
  • Amortisation, intangible assets other than goodwill excluding depreciation of government subsidies24 · Dec 2022 to Sep 2024
  • Non-current assets excluding the acquisition of rights arising from financial instruments, deferred tax assets, retirement benefit assets, and insurance contracts8 · Dec 2023 to Sep 2024
  • Non-current assets excluding the acquisition of rights arising from financial instruments, deferred tax assets, retirement benefit assets, and insurance contracts8 · Dec 2022 to Mar 2024

Segments

936 facts

Figures broken down by business line, region, product or another axis the company reports on.

Segments7 members · 324 facts

  • CdmoMemberOfSegmentsMemberOfDisclosureOfOperatingSegmentsTableOfMember76 · Dec 2022 to Sep 2025
  • DevelopmentAndCommercializationOfBiopharmaceuticalsMemberOfSegmentsMemberOfDisclosureOfOperatingSegmentsTableOfMember76 · Dec 2022 to Sep 2025
  • CdmoMemberOfReportableSegmentsMemberOfDisclosureOfOperatingSegmentsTableOfMember64 · Dec 2024 to Sep 2026
  • BiopharmaceuticalDevelopmentAndCommercializationMemberOfSegmentsMemberOfDisclosureOfAssetsAndLiabilitiesForOperatingSegmentsTitleTableOfMember34 · Dec 2023 to Sep 2025
  • CdmoMemberOfSegmentsMemberOfDisclosureOfAssetsAndLiabilitiesForOperatingSegmentsTitleTableOfMember34 · Dec 2023 to Sep 2025
  • CdmoMemberOfReportableSegmentsMemberOfDisclosureOfAssetsAndLiabilitiesForOperatingSegmentsTableOfMember32 · Dec 2024 to Sep 2026
  • BiopharmaceuticalDevelopmentAndCommercializationMemberOfReportableSegmentsMemberOfDisclosureOfAssetsAndLiabilitiesForOperatingSegmentsTableOfMember8 · Dec 2024 to Dec 2025

Geographical areas7 members · 254 facts

  • CountryOfDomicileMember71 · Dec 2022 to Sep 2026
  • OtherCountriesMember48 · Dec 2022 to Sep 2026
  • AmericasMemberOfForeignCountriesMemberOfDisclosureOfGeographicalAreasTableOfMember40 · Dec 2022 to Mar 2026
  • EuropeMemberOfForeignCountriesMemberOfDisclosureOfGeographicalAreasTableOfMember40 · Dec 2022 to Mar 2026
  • ForeignCountriesMember23 · Dec 2022 to Sep 2026
  • AmericasMember16 · Jun 2025 to Sep 2026
  • EuropeMember16 · Jun 2025 to Sep 2026

Products and services3 members · 196 facts

  • OtherRevenueMemberOfProductsAndServicesMemberOfDisclosureOfProductsAndServicesTableOfMember96 · Dec 2022 to Sep 2026
  • RevenueFromSaleOfGoodsProductMemberOfProductsAndServicesMemberOfDisclosureOfProductsAndServicesTableOfMember92 · Dec 2022 to Sep 2026
  • RevenueFromSaleOfGoodsAndMerchandiseProductMemberOfProductsAndServicesDomainOfDisclosureOfProductsAndServicesTableOfMember8 · Sep 2025 to Sep 2026

Segment consolidation items2 members · 162 facts

  • OperatingSegmentsMember138 · Dec 2022 to Sep 2026
  • EliminationOfIntersegmentAmountsMember24 · Dec 2024 to Jun 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of SAMSUNG BIOLOGICS CO.,LTD. (207940.KS) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

SAMSUNG BIOLOGICS CO.,LTD. (207940.KS): FY2025 revenue ₩4.56T · FactIQ